GOLETA, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) announced today the launch of a proposed secondary public offering of 2,100,775 shares of its common stock. All of such shares will be offered and sold by certain stockholders of Inogen, and the selling stockholders will receive all of the proceeds from such offering. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 315,116 shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Inogen will not sell any shares in the offering, nor will it receive any proceeds from the sale of the shares.
J.P. Morgan is acting as sole book-running manager for the offering, William Blair is acting as lead manager, and Leerink Partners and Needham & Company are acting as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained (when available) at the SEC's website at www.sec.gov or from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated public offering. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including the risks and uncertainties associated with market conditions and the completion of the public offering on the anticipated terms or at all. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2013 and in Inogen's subsequent reports on Form 10-Q and Form 8-K. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
CONTACT: Investor Relations contact: 805-562-0500 ext: 7